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Exosomes are small membranous vesicles secreted by a number of cell types including
neurons and can be isolated from conditioned cell media or bodily ﬂuids such as urine and
plasma. Exosome biogenesis involves the inward budding of endosomes to form multi-
vesicular bodies (MVB). When fused with the plasma membrane, the MVB releases the
vesicles into the extracellular environment as exosomes. Proposed functions of these vesi-
cles include roles in cell–cell signaling, removal of unwanted proteins, and the transfer of
pathogens between cells. One such pathogen which exploits this pathway is the prion, the
infectious particle responsible for the transmissible neurodegenerative diseases such as
Creutzfeldt–Jakob disease (CJD) of humans or bovine spongiform encephalopathy (BSE)
of cattle. Similarly, exosomes are also involved in the processing of the amyloid precursor
protein (APP) which is associatedwithAlzheimer’s disease. Exosomes have been shown to
contain full-length APP and several distinct proteolytically cleaved products of APP, includ-
ing Aβ. In addition, these fragments can be modulated using inhibitors of the proteases
involved in APP cleavage.These observations provide further evidence for a novel pathway
in which PrP andAPP fragments are released from cells. Other proteins such as superoxide
dismutase I and alpha-synuclein (involved in amyotrophic lateral sclerosis and Parkinson’s
disease, respectively) are also found associated with exosomes. This review will focus on
the role of exosomes in neurodegenerative disorders and discuss the potential of these
vesicles for the spread of neurotoxicity, therapeutics, and diagnostics for these diseases.
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INTRODUCTION
Most, if not all, types of mammalian cells release small membra-
nous vesicles known as exosomes. In addition to their protein con-
tent these vesicles have recently been shown to contain messenger
RNA (mRNA) and microRNA (miRNA) species. Roles for these
vesicles include cell–cell signaling, removal of unwanted proteins,
and transfer of pathogens, such as prions, between cells. Prions are
the infectious particles that are responsible for transmissible neu-
rodegenerative diseases such as Creutzfeldt–Jakob disease (CJD)
of humans or bovine spongiform encephalopathy (BSE) of cat-
tle. Proteins associated with certain neurodegenerative disorders,
such as Alzheimer’s and Parkinson’s disease and the prion diseases
CJD and BSE, can be selectively incorporated into intraluminal
vesicles of MVBs and subsequently released into the extracellular
environment in exosomes.As exosomes can be isolated fromcircu-
lating ﬂuids such as serum, urine, and cerebrospinal ﬂuid (CSF),
they provide a potential source of biomarkers for neurological
conditions. This review will describe the roles these vesicles play
in neurodegenerative disease and their potential for diagnostics
through the analysis of their protein and genetic cargo.
EXOSOME BIOGENESIS AND PROTEIN SORTING
Exosome biogenesis occurs within multivesicular bodies (MVBs)
in the endosomal system, which co-ordinates cargo transport
between the plasma membrane, trans-Golgi network (TGN), and
lysosomes. Collectively, the endosomal system consists of primary
endocytic vesicles, early endosomes, and MVBs. Early endosomes
are located near the cell membrane where they act as the ﬁrst port
of call for primary endocytosed vesicles which are either recycled
to the plasma membrane or targeted to MVBs. Proteins that are
sequestered to the limiting membrane of MVBs can be selectively
incorporated into intraluminal vesicles (ILVs) by invagination of
the MVB membrane. From here, proteins are either degraded by
fusion of the MVB with the lysosomal membrane and release of
the ILV’s into the lysosome, or alternatively, they can be released
into the extracellular environment as exosomes when MVBs fuse
with the plasma membrane (Figure 1). Protein sorting and pack-
aging into ILVs occurs in a regulated manner, involving a variety
of mechanisms including mono-ubiquitination and the ESCRT
(endosomal sorting complex required for transport) machinery
(Hicke, 2001), association with lipid rafts (de Gassart et al., 2003),
higher-ordered oligomerization (Vidal et al., 1997; Fang et al.,
2007), and segregation into microdomains by ceramide (Trajkovic
et al., 2008).
The existence of multiple mechanisms for protein sorting into
exosomes has raised the possibility that the various pathways
could generate multiple populations of MVBs, containing ILVs
with potentially distinct properties and fates (van Niel et al., 2006;
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FIGURE 1 | Exosome biogenesis occurs within MVBs of the endosomal
system. Following endocytosis into early endosomes (EE), the cargo is
packaged into ILVs within MVBs upon inward budding of the membrane. Four
different mechanisms have been described to facilitate this process:
mono-ubiquitination and the ESCRT machinery; association with lipid rafts;
higher-ordered oligomerization; and segregation into microdomains by
ceramide. MVBs can then fuse with lysosomes resulting in degradation of the
cargo, or alternatively, the MVBs can fuse with the plasma membrane,
resulting in release of the ILVs as exosomes, a process which is regulated by
Rab GTPases.
Simons andRaposo, 2009). TheMVBs could vary in the amount of
ILVs that are generated; the content of the ILVs; and also the ulti-
mate fate of the ILVs, either targeted to lysosomes for degradation
or released into the extracellularmatrix as exosomes. Theprocesses
that govern the sorting of neurodegenerative disease related pro-
teins into ILVs could therefore pre-determine the fate of these
proteins, and thus play a role in disease progression. However, it is
important to keep inmind that redundant pathways are a common
phenomenon in biology, and therefore multiple mechanisms may
be responsible for sorting various proteins into exosomes. Like-
wise sorting mechanisms involved may not be mutually exclusive
and additional pathways could exist to compensate for disrupted
pathways.
THE ROLE OF EXOSOMES IN PRION AND ALZHEIMER’S
DISEASES
Prion diseases are fatal, transmissible neurodegenerative disorders
that include CJD and Gerstmann–Straüssler–Scheinker Syndrome
(GSS) in humans, bovine spongiform encephalopathy (BSE) in
cattle and scrapie in sheep. In humans, prion disease occurs in
sporadic, familial and acquired etiologies. However, all forms of
the disease are transmissible, with possible routes of infection
through dietary exposure, medical procedures, and blood trans-
fusion (reviewed in Aguzzi and Heikenwalder, 2006). According
to the protein-only hypothesis of prion propagation, an abnormal
isoform of the cellular form of the prion protein (PrPC), which
is referred to as PrPSc, is the sole or major component of the
infectious prion agent (Prusiner, 1982). The normal prion protein
isoform, PrPC, is encoded by PRNP and is expressed in all tissues
of the human body, with the highest levels of expression observed
in tissues of the central nervous system and brain.
Both PrPC and PrPSc have been isolated in association with
exosomes, and PrPSc containing exosomes were infectious in both
animal and cell bioassays (Fevrier et al., 2004; Vella et al., 2007;
Alais et al., 2008). In addition, cells loaded with puriﬁed PrPSc
have been found to transfer between cells in vitro using tunneling
nanotubes (Gousset et al., 2009). While tunneling nanotubes can
traverse only short distances, exosomes are capable of traveling
long distances, and are thus of interest in the peripheral spread
of prions. Interestingly, a recent study found exosomes were able
to traverse along tunneling nanotubes, suggesting many of these
intercellular modes of transport may not be completely indepen-
dent of one another (Mineo et al., 2012). Although these studies
have primarily utilized cultured cell systems to isolate the exo-
somal vesicles, primary cultured neurons (Faure et al., 2006) and
CSF (Vella et al., 2008) have also been used as a source of exosomes
in which PrPC has been detected.
The exosome membrane contains lipid rafts enriched in cho-
lesterol, sphingomyelin and ganglioside GM3 (Wubbolts et al.,
2003) and externalized phosphatidylserine (Morelli et al., 2004)
which are believed to participate in vesicle structure and func-
tion, and trafﬁcking of particular proteins to exosomes (de Gassart
et al., 2003). PrPC is tethered to the plasma membrane by a
glycosylphosphatidyl-inositol (GPI) anchor, and the conversion
of PrPC to PrPSc has been suggested to occur in lipid raft regions
(Taylor and Hooper, 2006). Additionally, an interaction between
an N-terminal domain of PrP and a postulated lipid raft resident
protein or lipid can occur on the membrane (Taylor and Hooper,
2006). GPI tethering is also likely to hold true in exosomes as phase
partitioning experiments with Triton X-114 have shown that exo-
somal PrPC migrates to the detergent phase, consistent with it still
containing a GPI anchor (Vella et al., 2007). The presence of lipid
rafts in exosomes could also aid in its ability to transmit PrPSc. One
study suggested that the generation of new PrPSc during infection
required the insertion of PrPSc into lipid rafts (Baron et al., 2002).
Hence it is plausible to speculate that the exosome containing
PrPSc may be able to insert its PrPSc cargo into the membrane
of recipient cells upon contact. Another function of the lipid raft
nature of exosomes may be to stabilize a particular infectious iso-
form of PrPSc. Similar effects have been observed in cell free PrP
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conversion systems where lipids have been found to assist in the
formation of de novo PrPSc, presumably by acting to stabilize or
align intermediary isoforms (Deleault et al., 2007; Wang et al.,
2007, 2010).
Alzheimer’s disease (AD) is the most common form of demen-
tia in humans and is characterized pathologically by the extracel-
lular deposition of insoluble amyloid plaques comprised of the
β-amyloid peptide (Aβ), a 39–43 amino acid peptide produced by
proteolytic cleavage of the amyloid precursor protein (APP; Cai
et al., 1993; Findeis, 2000; Serpell and Smith,2000;Murakami et al.,
2002). The amyloidogenic pathway of APP processing involves
sequential cleavage by β- and γ-secretases. β-Secretase cleaves at
the amino-terminus of Aβ (Seubert et al., 1993; Mattson, 1997)
resulting in the release of secreted APP, and leaves intact Aβ as a
membrane-associated, 99-amino-acid carboxy-terminal fragment
(β-CTF). β-CTF can undergo endocytosis via clathrin-coated vesi-
cles (Selkoe, 1996) and is trafﬁcked to various endosomal com-
partments, including MVBs, from which exosomes are derived
(Yamazaki et al., 1996).The initial link between Aβ and its asso-
ciation with exosomes proposed that intracellular-accumulated
Aβ in MVBs is incorporated into exosomes and released into the
extracellular environment (Rajendran et al., 2006; Sharples et al.,
2008). The identiﬁcation of Aβ in association with exosomes is an
important ﬁnding, especially as other exosomal proteins such as
Alix and Flotillin-1 have been found to accumulate in the plaques
of brains from patients with AD (Rajendran et al., 2006). Exo-
somes could also provide an explanation for transport of Aβ and
the equally toxic APP-CTFs around the body to the brain, where
they contribute to amyloid deposition.
PRION LIKE MECHANISMS IN OTHER NEURODEGENERATIVE
DISEASES
While prion diseases have long been thought to be the only neu-
rodegenerative disease that is infectious and capable of spreading
between individuals, key proteins involved in other neurodegener-
ative diseases such as Alzheimer’s, Parkinson’s and ALS may share
similar behavioral features as prions (Table 1). At a basic biochem-
ical level, misfolding and aggregation of these proteins can occur
through seeded polymerization which has an initial, lengthy lag
phase. However, this lag phase can be largely eliminated through
the introduction of an already misfolded seed. Like prions, these
aggregates appear to be able to persistently self-propagate, and
there is also evidence of spreading from cell-to-cell and through-
out the CNS. The spreading of these aggregates is no more obvious
than when the neuropathology and deposition of the pathological
proteins during these diseases is examined.
A considerable number of in vivo studies during the last half
century have shown that prions from one diseased source can
be introduced into an otherwise healthy animal and cause PrPSc
formation and clinical prion disease. However it wasn’t until the
mid-nineties when a similar experiment was conducted in which
brain extracts from human Alzheimer’s patients were injected into
otherwise healthy primates and the formation of amyloid plaques
was observed in the site of injection, and adjacent brain regions
(Baker et al., 1994). These observations have since been repro-
duced in murine models of Alzheimer’s disease (Kane et al., 2000;
Meyer-Luehmann et al., 2006; Morales et al., 2011). Similarly, tau
misfolding can be induced in transgenic mice by injection of tis-
sue homogenates containing aggregated tau (Clavaguera et al.,
2009). This phenomenon has also been observed in humans when
patients with Parkinson’s disease received grafts of normal neu-
ronal stem cells. Uponpost-mortem examination it was found that
the grafts contained α-synuclein inclusions that could only have
arisen through transmission or spread from diseased brains (Kor-
dower et al., 2008; Li et al., 2008). Interestingly, brain homogenates
containing α-synuclein aggregates, when injected into transgenic
mice, were also found to be able to initiate both aggregation of
α-synuclein and the onset of clinical symptoms (Hansen et al.,
2011). Given the intracellular origin of exosomes, they present a
potential pathway in which cytosolic neurodegenerative disease
related proteins are released into the extracellular space. In fact,
a number of neurodegenerative disease related cytosolic proteins
have already been found to be contained within exosomes such
as α-synuclein (Emmanouilidou et al., 2010; Alvarez-Erviti et al.,
2011a) and tau (Saman et al., 2011). SOD1 has also been found
released in association with exosomes from a cell model of ALS
(Gomes et al., 2007).
Inoculation of permissive cell lines with brain homogenates
from prion infected mice results in infection of cells with prions,
and continual replication of PrPSc that ampliﬁes over time with
increased passage of cells (Vella et al., 2007; Courageot et al., 2008;
Vilette, 2008). Similar observations can be seen with other neu-
rodegenerative diseases. Cultured neuronal cells incubated with
tau aggregateswere found to takeupﬁbrils in an endocyticmanner,
and subsequently induce ﬁbrillization of cytoplasmic tau (Frost
et al., 2009;Guo and Lee, 2011). The newly aggregated intracellular
tau was also capable of transferring between co-culture cells (Frost
et al., 2009). Likewise polyglutamine peptide aggregates can also be
taken up by cultured cells and sequestered into aggresomes, where
they can recruit cytoplasmic proteins and transfer the aggregates
between co-cultured cells (Ren et al., 2009). The application of
exogenous recombinant aggregated α-synuclein to cultured cells
has also been found to be efﬁcient at seeding aggregation of its
intracellular counterpart, and subsequent transfer between cells
by a number of groups (Danzer et al., 2009; Desplats et al., 2009;
Hansen et al., 2011; Volpicelli-Daley et al., 2011).
Most recently, mutant SOD1 aggregates have been shown to be
able to enter neuronal cells where they can seed aggregation of the
normal, cytoplasmic mutant SOD1 (Munch et al., 2011). Upon
removal of the seed, aggregation persists, suggesting these newly
formed endogenous aggregates are capable of continually seeding
further aggregation in a mechanism similar to PrPSc. Although
it is unclear if exosome associated SOD1 is pathogenic, a mutant
form of SOD1 was able to pass from cells through a 0.4 μm ﬁlter
and propagate in recipient cells (Munch et al., 2011). This suggests
that mutant SOD1 aggregate seeds are less than 0.4 μm and/or the
aggregates are contained within exosomes. A similar experiment
has been performed using these 0.4 μm ﬁlters to demonstrate that
PrPSc canbe transferred fromone cell to anotherwithoutdirect cell
contact, thus suggesting involvement of exosomes in this process
(Alais et al., 2008).
Prion infectivity and seeding ability has been detected in the
CSF of prion infected animals and humans (Atarashi et al., 2007,
2008, 2011; Wilham et al., 2010; Orru et al., 2012), and exosomes
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isolated from sheep CSF are enriched in PrPC (Vella et al., 2008).
Therefore it is plausible that some infectivity may be released into
the CSF in association with exosomes in infected animals. Inter-
estingly, exosomal markers were found to be enriched in amyloid
plaques in the brains of mice (Kokubo et al., 2005) and post-
mortem human AD patients (Rajendran et al., 2006), suggesting
exosomes played a role in trafﬁcking of Aβ aggregates to these
sites during disease progression. Monomeric and oligomeric α-
synuclein and tau have also been found in blood and CSF in
PD and AD patients (Vandermeeren et al., 1993; El-Agnaf et al.,
2006; Tokuda et al., 2010; Bruggink et al., 2011), suggesting release
from the CNS possibly in association with exosomes. Phosphory-
lated tau was also found in exosomes from human CSF in early
Alzheimer’s disease (Saman et al., 2011). Together, these obser-
vations provide strong evidence for the in vivo involvement of
exosomes in neurodegenerative disease. While there is mounting
evidence demonstrating exosomes maybe involved in the spread
of pathogenic neurodegenerative disease related proteins, it is
unknown whether they act purely as a transport mechanism or
perhaps their structural and molecular makeup aid in the process.
EXOSOME STRUCTURE AND FUNCTION IN
NEURODEGENERATIVE PROTEIN TRANSFER
Exosomes contain an array of different proteins; some are spe-
ciﬁc to the cell type of origin, while others are common across all
exosomes. As a result of their endosomal origins exosomes con-
tain proteins involved in membrane fusion and transport such
as the Annexins and Rab proteins. Exosomes also contain heat
shockproteins,adhesionmolecules,metabolic enzymes,cytoskele-
tal proteins and are heavily enriched in tetraspanins such as CD63
and CD81 [as discussed in a number of reviews including (Thery
et al., 2002; Schorey and Bhatnagar, 2008)] (Figure 2). It is sus-
pected that proteins on the surface of exosomes aid in their uptake
by recipient cells. Using proteases to shave off surface proteins
of both exosomes and/or cells has been shown to reduce cellular
uptake of exosomes (Escrevente et al., 2011), suggesting proteins
on the surface of cells and exosomes act asmediators for facilitating
fusion. It has also been shown that exosome transfer is inhibited
at 4˚C (Escrevente et al., 2011). These observations suggest exo-
some uptake is not a passive process, but is energy dependent and
mediated by protein receptors.
Unlike the spread of prions via exosomes which need only
surface interaction, transfer of the cytosolic neurodegenerative
proteins into the recipient cells require the exogenous transporter
exosomes to fuse with the plasma membrane. Direct fusion with
the plasmamembrane and release of contents into cytosol has been
demonstrated with the use of luciferin-loaded exosomes which
“injected” their intraluminal content into the cytosol of the tar-
get dendritic cells (Montecalvo et al., 2012). A similar mechanism
is likely to occur when cationic liposomes were used to deliver
α-synuclein ﬁbrils to cultured cells (Luk et al., 2009). The lipo-
somes fused with the plasma membrane, delivering their exoge-
nous α-synuclein ﬁbrils and induced formation of Lewy-body like
structures in the cytoplasm of the recipient cell. Similarly, it was
found that combining puriﬁed PrPSc with microsomes or lipo-
somes improved the efﬁciency of the PrPSc as an inoculum in
cell infections (Gabizon et al., 1988; Baron et al., 2006). Exosomes
could potentially function in a similar manner to microsomes or
liposomes by direct fusion with the plasma membrane improving
the cellular uptake of prions or other neurodegenerative disease
associated proteins.An alternative uptakemechanismof exosomes
through endocytosis has been observed in rat neuronal PC12 cells
with the endocytosed exosomes being trapped in cytosolic vesicles,
and subsequently transported to the perinuclear regionwhere they
accumulate as large organelles (Tian et al., 2010). It is also possi-
ble that following endocytosis, back fusion can occur between the
exosomal membrane and the limiting membrane of the endocytic
compartment, thus releasing the exosomes luminal contents into
the cytosol. Finally, aggregated proteins can damage lipid bilayers
and form pores (Tsigelny et al., 2008) – a process which could
occur post endocytosis releasing the misfolded proteins into the
cytosol where they can seed further aggregation of the normal
endogenous proteins.
ROLE OF EXOSOMAL SHUTTLE RNA IN
NEURODEGENERATIVE DISEASE
Since their discovery, exosomes were thought to contain lipids and
proteins with no genetic material (Johnstone et al., 1987). How-
ever, Ratajczak et al. (2006) reported that microvesicles, which
are circular membrane vesicles 100–1000 nm shed directly from
the plasma membrane, contained RNA. While Valadi et al. (2007)
demonstrated that exosomes isolated from human and mouse
mast cells contain both mRNA and miRNA,but no DNA. miRNA’s
are a class of non-coding RNA (ncRNA) species of approximately
22 nucleotides in length that function by post-translational repres-
sion of target mRNA’s by binding to their 3′ untranslated regions
(Bartel, 2004). Valadi et al. (2007) demonstrated that the exoso-
mal RNA differed from that of donor cells from which they were
derived, contained little or no ribosomal RNA and were enriched
in small RNA species. Transfer experiments revealed that exoso-
mal RNA is shuttled between donor and recipient mast cells and
remained functional upon uptake in the recipient cell cytoplasm.
Collectively these miRNA and mRNA species have been termed
“exosomal shuttle RNA” (esRNA). esRNA was also shown to be
contained and protected from degradation within the exosome
vesicles themselves and it was proposed that exosome-mediated
transfer of esRNA is a novel mechanism of genetic exchange
between cells, either in the microenvironment or over a distance.
esRNA has since been isolated from exosomes derived from
cancer cells, stem cells and dendritic cells (Taylor and Gercel-
Taylor, 2008; Rabinowits et al., 2009); and biological ﬂuids such
as peripheral blood (Hunter et al., 2008), serum (Skog et al.,
2008; Taylor and Gercel-Taylor, 2008), and saliva (Michael et al.,
2010). Moreover, several studies have demonstrated a functional
role of miRNA mediated transfer of exosomes to recipient cells
(Valadi et al., 2007; Kosaka et al., 2010; Pegtel et al., 2010; Yang
et al., 2011; Montecalvo et al., 2012). Tumor-suppressive miRNA’s
have been shown to be functional when transferred by exosomes
in a ceramide dependent manner in prostate cancer cell lines
(Kosaka et al., 2010). While immature and mature dendritic cells
can package and release miRNA in exosomes dependent upon
their activation state, with released exosomes fusing with recipient
cell plasma membranes transferring functional miRNA into the
cytosol (Montecalvo et al., 2012). Macrophages can also regulate
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FIGURE 2 | Exosomes are small membrane bound vesicles sharing
similar topology to the plasma membrane.They contain mRNA and
miRNA, and a vast array of different proteins depending on their host cell.
However they are generally all enriched in proteins involved in MVB
formation, tetraspanins, membrane transport and fusion and a number of
cytosolic proteins. In addition to these generic proteins, proteins associated
with neurodegenerative diseases such as Alzheimer’s, Prion disease, and
Parkinson’s disease have been identiﬁed in exosomes.
the invasiveness of breast cancer through exosome-mediated deliv-
ery of miRNA into cells promoting metastasis (Yang et al., 2011).
Exosomes can also functionally deliver ncRNA, retroviral RNA
repeats and tRNA sequences which are subsequently incorporated
into RNA-silencing pathways (Gibbings et al., 2009; Lee et al.,
2009; Haussecker et al., 2010). Likewise, tumor microvesicles have
been demonstrated to contain elevated levels of speciﬁc coding,
ncRNA and retrotransposon RNA transcripts from endogenous
retroviruses that could be horizontally transferred during cancer
progression (Balaj et al., 2011). These observations suggest that
exosomes package and functionally deliver genetic components
such as mature miRNA, mRNA, ncRNA, and retroviral RNA to
the microenvironment, strongly supporting the role of exosomes
in gene regulation mechanisms and intercellular communication.
Exosomes have been described to be released from a variety of
neuronal cells types including microglial cells (Potolicchio et al.,
2005), developing neurons (Faure et al., 2006), cultured astrocytes
(Taylor et al., 2007), and oligodendrocytes (Kramer-Albers et al.,
2007). Additionally, they have been shown to play a role in the
normal physiology and synaptic plasticity of the central nervous
system, with secretion of exosomes being regulated by calcium
inﬂux and glutamatergic synaptic activity in cortical and hip-
pocampal neurons (Lachenal et al., 2011). Therefore, it is plausible
to suggest that functional transfer of esRNA plays a signiﬁcant
yet uncharacterized role in the progression of neurodegenerative
disorders such as Prion diseases, Alzheimer’s disease, and other
related disorders.
The nervous system is a rich source of miRNA expres-
sion, with estimates suggesting that neuronal miRNA’s can post-
transcriptionally modulate the expression of more than a third of
the coding mRNAs (Kosik, 2006). While the functions of many
discovered miRNA’s so far remain unknown, some miRNA’s have
been shown to play a role in several biological processes including
proliferation, organ development, cell differentiation, apoptosis,
and infectious disease (Croce and Calin, 2005). The role of dereg-
ulated miRNA has also been implicated in cancer, with evidence
suggesting that aberrant miRNA expression can function both as
tumor suppressors and oncogenes (Esquela-Kerscher and Slack,
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2006). Aberrant miRNA expression has also been identiﬁed as a
factor in neurodegenerative related disorders (reviewed in Hebert
and De Strooper, 2007, 2009); with Table 2 summarizing miRNA’s
implicated in Prion diseases, Alzheimer’s disease, Parkinson’s, and
Tauopathies.
In Alzheimer’s disease, miRNA’s have been shown to target the
3′ UTR of several key genes by regulating the expression and func-
tion of APP and BACE (the enzyme responsible for β-secretase
cleavage of APP) in cell culture models of AD (Hebert et al., 2008,
2009; Patel et al., 2008; Boissonneault et al., 2009; Vilardo et al.,
2010; Long and Lahiri, 2011). Extensive studies on post-mortem
humanADbrain samples and in transgenicADmousemodels also
identiﬁed several miRNA that are signiﬁcantly deregulated during
the disease process (Lukiw andPogue, 2007; Sethi and Lukiw,2009;
Nelson and Wang, 2010; Schonrock et al., 2010, 2012; Shioya et al.,
2010; Li et al., 2011; Wang et al., 2011; Lukiw and Alexandrov,
2012).
Deregulated miRNA expression has also been suggested as a
mechanism for failure of proteosomal degradation of insoluble-
and phosphorylated-tau proteins in tauopathies (Carrettiero et al.,
2009), while a number of brain miRNA’s have been shown to
regulate the ratio of tau 3-repeat and 4-repeat isoforms causing
progressive supranuclear palsy (Smith et al., 2011; Wanet et al.,
2012). Interestingly genetic ablation of Dicer, which is responsible
for mature miRNA biogenesis, in adult forebrain neurons results
in hyperphosphorylation of tau, neuronal loss in the hippocam-
pus, and cellular shrinkage in the cortex (Hebert et al., 2010). The
hyperphosphorylation of tau was subsequently demonstrated to
involve up-regulation of ERK kinases by deregulation of miR-15
in AD brains (Hebert et al., 2010).
Downregulation of miRNA’s 133b and miR-34b/34c has been
demonstrated in Parkinson’s disease mid-brain dopaminergic
neurons (Kim et al., 2007; Minones-Moyano et al., 2011), while
miR-7 and miR-153 can regulate expression of α-synuclein 3′ UTR
(Junn et al., 2009; Doxakis, 2010). Moreover, pathogenic LRRK2
can cause familial as well as sporadic Parkinson’s disease char-
acterized by age-dependent degeneration of dopaminergic neu-
rons, possibly due to inhibition of miR-7 mediated translational
repression of α-synuclein (Gehrke et al., 2010).
A miRNA signature in prion disease has been reported in prion
infected mice and primates (Saba et al., 2008; Montag et al., 2009).
Both studies examined themiRNAproﬁle in brain tissue after clin-
ical symptoms of disease were well-established and determined a
subset of miRNA’s to be signiﬁcantly deregulated. In prion infected
Table 2 | Dysregulation of miRNA’s in neurodegenerative diseases.
Neurodegenerative
disease
Deregulated miRNA Reference
Prion diseases let-7b, miR-128, miR-139-5p, miR-146a, miR-320, miR-328 and miR-342-3p Saba et al. (2008)
miR-342-3p and miR-494 Montag et al. (2009)
miR-146a Lukiw et al. (2011), Saba et al. (2012)
Alzheimer’s disease miR-9, miR-124, miR-125b, miR-128, miR-132 and miR-219 Lukiw and Pogue (2007)
miR-9, miR-29a and miR-29b Hebert et al. (2008)
miR-106a and miR-520c Patel et al. (2008)
miR-107 Wang et al. (2008), Nelson andWang (2010)
miR-298 and miR-328 Boissonneault et al. (2009)
miR-17-5p, miR-20, and miR-106b Hebert et al. (2009)
miR-9, miR-125b and miR-146a Sethi and Lukiw (2009)
miR-146a Li et al. (2011), Lukiw et al. (2011)
miR-101 Vilardo et al. (2010), Long and Lahiri (2011)
miR-9 and miR-191c Schonrock et al. (2010), Schonrock et al. (2012)
miR-29a Shioya et al. (2010)
miR-15, miR-107, miR-29a, miR-29b, miR-212, miR-424 Wang et al. (2011)
miR-125b and miR-146a Lukiw and Alexandrov (2012)
Parkinson’s disease miR-133b Kim et al. (2007)
miR-7 Junn et al. (2009)
miR-7 and miR-153 Doxakis (2010)
miR-7 and miR-184* Gehrke et al. (2010)
miR-34b and miR-34c Minones-Moyano et al. (2011)
Tauopathies miR-128 Carrettiero et al. (2009)
miR-15 Hebert et al. (2010)
miR-9, miR-124, miR-132 and miR-137 Smith et al. (2011)
miR-132 and miR-212 Wanet et al. (2012)
miRNA that has been shown to be deregulated in a number of neurodegenerative diseases are underlined.
miRNA deregulated in individual neurodegenerative disease and validated by independent studies are indicated in bold.
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mice, Saba et al. (2008) identiﬁed 15 miRNA’s to be signiﬁcantly
deregulated upon prion infection including up-regulation of miR-
342-3p and miR-146a. miR-342-3p was also up-regulated in prion
infected primate cynomolgus macaques and in brain tissue of
type-1 and type-2human sporadicCJDcases (Montag et al., 2009).
Up-regulation of miR-146a during prion infection is proposed to
involve inﬂammatory responsepathways and correlateswithdepo-
sition of prion plaques and activation of surrounding microglia
(Saba et al., 2012). Up-regulated miR-146a was also observed in
human neuronal–glial primary cell co-cultures challenged with
ﬁve different species of single- or double-stranded DNA or RNA
neurotrophic viruses, pro-inﬂammatory cytokines, Aβ42 peptide,
metal-induced neurotoxicity, and oxidative stress. Furthermore,
miR-146a up-regulation was also observed in murine scrapie, in
AD brains, and rare human prion disorders, including sporadic
CJD and GSS (Lukiw et al., 2011). These results suggest that miR-
146a up-regulation in human brain cells is a general mechanism
of innate immune response and antiviral immunity (Lukiw et al.,
2011).
Despite the increasing body of evidence implicating dys-
regulated miRNA expression in a number of neurodegenerative
disorders and exosomes are implicated in the pathogenic trans-
fer of neurotoxic proteins in these diseases, very little research
has focused on the potential role of esRNA in pathogenesis
and diagnosis of neurological diseases. Given that several stud-
ies have successfully identiﬁed miRNA proﬁles from circulating
exosomes isolated from plasma and serum samples in the diagno-
sis of human diseases including ovarian cancer, glioblastoma, and
lung adenocarcinoma (Skog et al., 2008; Taylor and Gercel-Taylor,
2008; Rabinowits et al., 2009), then it is plausible to suggest that
miRNA proﬁling can be applied to diagnosis in other diseases.
Recently, it has been reported that extracellular miRNA released
from cells in plasma can associate in two populations, both depen-
dent and independent of exosomes either bound toAGO2 (Arroyo
et al., 2011; Turchinovich et al., 2011) or high-density lipoproteins
(Vickers et al., 2011). Therefore, targeted exosomal puriﬁcation
strategies for enrichment of circulating miRNA biomarkers may
be required to increase biomarker sensitivity.Moreover, circulating
exosomes isolated for the study of Prion, Alzheimer’s, Parkinson’s,
and other related disorders represent a unique subset of exosomal
populations that can be enriched by targeting the deﬁned toxic
protein biomarkers associated with these disorders. This strategy
can then be coupled to small RNA next generation sequencing
technologies to accurately determine circulating exosomal miRNA
signatures speciﬁc to individual diseases.
POTENTIAL OF EXOSOMES IN NEURODEGENERATIVE
DISEASE THERAPEUTICS?
With the discovery that exosomes are able to transmit protein,
mRNA and miRNA between cells, the possibility arose that exo-
somes could be exploited as vehicles for delivering therapeutic
compounds in vivo (Valadi et al., 2007; Simons and Raposo, 2009;
Sun et al., 2010). Since the development of RNA interference
(RNAi), much work has been carried out to utilize this technology
for treatment of various diseases. However, many barriers were
encountered, plaguing clinical translation of this technology. One
of the biggest issues faced is the ability to target speciﬁc tissues
and at therapeutic doses without eliciting immune responses and
inducing toxicity (van den Boorn et al., 2011). Current approaches
for clinical application of RNAi include usage of viral and synthetic
carrier systems such as liposomes and nanoparticles. However,
there are several disadvantages with these systems. Viral parti-
cles can be cleared from the body by antibodies and also has the
potential to activate immune responses, making repeated admin-
istration challenging (Waehler et al., 2007). Harnessing exosomes,
the body’s own intercellular delivery mechanism, would there-
fore provide a breakthrough for the ﬁeld of drug delivery and it
would bypass many issues such as immune activation, acceptance
by target cells, and prevent degradation of cargo.
In a recent study, the ﬁrst steps toward the application of exo-
somes as a drug delivery vehicle was taken. Using exosomes from
immature murine dendritic cells, Alvarez-Erviti et al. (2011b)
modiﬁed the exosomes to express a fusion of the exosomal mem-
brane protein Lamp2b and a neuron-speciﬁc RVG peptide. The
exosomes were then loaded with siRNA for BACE1, a protein
implicated in Alzheimer’s disease. Following intravenous injec-
tion, the exosomes were targeted to the neurons, microglia and
oligodendrocytes in the mouse brain, and was able to induce
knockdown of BACE1. This discovery highlighted the therapeu-
tic potential of exosome-mediated RNAi technology,with possible
applications in neurodegenerative diseases, such as prion disease
and Alzheimer’s disease, where the key mediators of these diseases
can be targeted for knockdown using this approach.
Despite the appeal, in order to apply this technology clinically,
a few issues still need to be addressed. Firstly, a stable source of
well characterized exosomes that can be expanded needs to be
established (van Dommelen et al., 2011). The process of loading
exosomes with siRNA will also require optimization in order to
achieve maximum efﬁciency and reduce the need to administer
large amounts of exosomes during therapy. Tissue-speciﬁc target-
ing of exosomes should also be further reﬁned to ensure both a
safe and speciﬁc delivery to target tissues, as well as efﬁcient dif-
fusion across the blood brain barrier. With further improvements
in techniques and technology, exosomes hold great potential to
revolutionize RNAi-mediated therapy, opening up a door to an
alternative, untapped source of clinical therapy.
The precise mechanisms that govern the packaging of esRNA
inside exosomes remain unanswered. While several potential
mechanisms can be postulated, the most logical explanation is
that RNA is packaged directly from the cytoplasm as a result of
initial invagination of the MVB into ILV’s. However, several stud-
ies have shown that exosomes contain little or no 18S and 28S
cellular ribosomal species; not all mRNA and miRNA contained
within cells can be detected in exosomes, and that some mRNA
and miRNA can be directly targeted and packaged in exosomes
(Valadi et al., 2007; Hunter et al., 2008; Taylor and Gercel-Taylor,
2008; Pigati et al., 2010; Montecalvo et al., 2012). These observa-
tions suggest that esRNA is selectively incorporated into ILV’s as
opposed to random events or contamination during the process
of exosome isolation.
CONCLUSION
As exosomes are being associated with an increasing num-
ber of neurodegenerative disorders they may provide a source
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of both protein and genetic biomarkers obtained from cir-
culating exosomes, as well as new insights into the observed
spreading of neuropathologic lesions common to these diseases.
One current drawback of using exosomes for biomarker dis-
covery is the methods that are used for their isolation (based
on ultracentrifugation and ﬁltration) as these methods are not
immediately amenable for high-throughput screening. The iden-
tiﬁcation of esRNA in exosomes provides an attractive tar-
get for biomarkers as demonstrated by the studies in brain
tumors. Applying the genetic analysis of exosomes from neu-
rodegenerative disorders such as prion diseases and AD may
identify suitable biomarkers that are applicable for diagnostic
applications.
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